To test this, we performed a first-in-human multi-center phase 1 trial (ClinicalTrials.gov NCT01885897 ) of the IL-15 superagonist complex ALT-803 in patients who relapsed >60 days after allo-HCT. ALT-803 was administered to 33 patients via the intravenous (IV) or subcutaneous (SQ) ...
ALT-803 is an IL-15 superagonist complex that has been developed as a potent antitumor immunotherapeutic agent and is in clinical trials. Here we describe the creation of a novel fusion molecule, 2B8T2M, using the ALT-803 scaffold fused to four single chains of the tumor-targeting monoclonal...
Randomized trial of behavior therapy for adults with Tourette syndrome. Arch Gen Psychiatry 2012;69(8):795-803. doi: 10.1001/archgenpsychiatry.2011.1528.Wilhelm S, Peterson AL, Piacentini J, et al. Randomized trial of behavior therapy for adults with Tourette syndrome....
This phase Ib clinical trial evaluated the safety and toleraibility of ALT-803, an IL-15 superagonist, plus BCG in patients with BCG-naive NMIBC. Methods: This is a Phase Ib trial using the 3+3 design to evaluate intravesical ALT-803 plus BCG 50 mg in BCG-naive NMIBC patients, who ...
20 We hypothesized that ALT-803 would augment donor NK and T-cell number and function in patients that have relapsed after allo-HCT to enhance donor antitumor immune responses and tested this in a first-in-human, investigator-initiated, multicenter phase 1 clinical trial. Methods Study design ...